Abstract
P2Y12 receptor mediated inhibition of platelet aggregation is one of the most explored and exploited pathways in antiplatelet drug therapy to prevent ischemic events in patients undergoing percutaneous coronary intervention (PCI) for the treatment of the acute coronary syndrome (ACS). Ticlopidine, Clopidogrel, Prasugrel, Ticagrelor, Cangrelor and Elinogrel are the P2Y12 inhibitors that act as antiplatelet drugs. In this review, the features of these drugs and the factors reported to be responsible for drug resistance or drug ineffectiveness were described. The features like drug metabolism, reversible or irreversible binding of drugs to their target protein and the mode of administration were observed to evolve along with the antiplatelet drugs. These features also include the drug-drug interactions, the pharmacogenetics and pharmacodynamics of P2Y12 inhibitors. We attempted to critically analyze how the desirable features were met by the P2Y12 inhibitors in the course of time. This review provides an overview of the evolution of P2Y12 inhibitors and may guide the researchers to develop better antiplatelet drugs in the future.
Keywords: Antiplatelet drugs, drug-drug interactions, P2Y12 inhibitors, pharmacogenetics, pharmacodynamics, platelet aggregation, acute coronary syndrome (ACS), Cangrelor, Elinogrel, thrombus growth
Current Pharmaceutical Design
Title:A Critical Appraisal of the Functional Evolution of P2Y12 Antagonists as Antiplatelet Drugs
Volume: 18 Issue: 12
Author(s): S. M.A. Fayaz, G. K. Rajanikant
Affiliation:
Keywords: Antiplatelet drugs, drug-drug interactions, P2Y12 inhibitors, pharmacogenetics, pharmacodynamics, platelet aggregation, acute coronary syndrome (ACS), Cangrelor, Elinogrel, thrombus growth
Abstract: P2Y12 receptor mediated inhibition of platelet aggregation is one of the most explored and exploited pathways in antiplatelet drug therapy to prevent ischemic events in patients undergoing percutaneous coronary intervention (PCI) for the treatment of the acute coronary syndrome (ACS). Ticlopidine, Clopidogrel, Prasugrel, Ticagrelor, Cangrelor and Elinogrel are the P2Y12 inhibitors that act as antiplatelet drugs. In this review, the features of these drugs and the factors reported to be responsible for drug resistance or drug ineffectiveness were described. The features like drug metabolism, reversible or irreversible binding of drugs to their target protein and the mode of administration were observed to evolve along with the antiplatelet drugs. These features also include the drug-drug interactions, the pharmacogenetics and pharmacodynamics of P2Y12 inhibitors. We attempted to critically analyze how the desirable features were met by the P2Y12 inhibitors in the course of time. This review provides an overview of the evolution of P2Y12 inhibitors and may guide the researchers to develop better antiplatelet drugs in the future.
Export Options
About this article
Cite this article as:
S. M.A. Fayaz, G. K. Rajanikant , A Critical Appraisal of the Functional Evolution of P2Y12 Antagonists as Antiplatelet Drugs , Current Pharmaceutical Design 2012; 18 (12) . https://dx.doi.org/10.2174/138161212799958558
DOI https://dx.doi.org/10.2174/138161212799958558 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Atypical Antipsychotic Drugs During Pregnancy. Their Effects on the Mother and Offspring
Current Women`s Health Reviews Neutrophil Cell Count is Related to Hypertension in Workers: A Cross- Sectional Study
Vascular Disease Prevention (Discontinued) Statins and Vulnerable Plaque
Current Pharmaceutical Design The Role of Vitamin D in Dyslipidemia and Cardiovascular Disease
Current Pharmaceutical Design Drug Metabolizing Enzymes and Transporters mRNA in Peripheral Blood Mononuclear Cells of Healthy Subjects: Biological Variations and Importance of Preanalytical Steps
Current Drug Metabolism Chronic Kidney Disease and Cardiovascular Disease: A Focus on Primary Care
Cardiovascular & Hematological Disorders-Drug Targets Recombinant Human Insulin-Like Growth Factor-1: A New Cardiovascular Disease Treatment Option?
Cardiovascular & Hematological Agents in Medicinal Chemistry Impact of Red Wine Consumption on Cardiovascular Health
Current Medicinal Chemistry Role of Phytomolecules in the Treatment of Obesity: Targets, Mechanisms and Limitations
Current Topics in Medicinal Chemistry Coexistence of Type-1 Diabetes Mellitus and Papillary Thyroid Carcinoma
Current Diabetes Reviews Patented Novelties in Immunoisolation for the Treatment of Endocrine Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Obesity- An Adverse Factor in Reproductive Age
Applied Clinical Research, Clinical Trials and Regulatory Affairs Cardiovascular Diseases in Pregnancy - A Brief Overview
Current Cardiology Reviews Biology and Regulatory Roles of Nuclear Lamins in Cellular Function and Dysfunction
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Targeting STAT1 in Both Cancer and Insulin Resistance Diseases
Current Protein & Peptide Science B Cells and Beyond: Therapeutic Opportunities Targeting Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Recent Trends in the Pharmacological Activity of Isoprenyl Phenolics
Current Medicinal Chemistry Frequency Domain and Entropy Analysis of Fetal Heart Rate: Appealing Tools for Fetal Surveillance and Pharmacodynamic Assessment of Drugs
Cardiovascular & Hematological Disorders-Drug Targets Potentials of Hydrogels in Cancer Therapy
Current Cancer Therapy Reviews Sex Steroids Regulation of Appetitive Behavior
Mini-Reviews in Medicinal Chemistry